araag2/HINT huggingface dataset:
Clinical trial NCT03060993 (phase 2, status: unknown status)
Conditions: chronic obstructive pulmonary disease (copd), breathlessness, exercise intolerance
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8, E73.8, E73.9, E74.12, K90.49
Drugs: cannabis, placebo
SMILES: CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  GOLD stage III or IV COPD (i.e., post-β2-agonist FEV1 of 50% predicted or less)

          -  Self-reported cigarette smoking history ≥10 pack yrs

          -  Currently taking long-acting beta-2 agonists and long-acting antimuscarinic agents
             (LABA/LAMAs) with or without an inhaled corticosteroid

          -  Willing to abstain from cannabis smoking for ≥15 days prior to study participation (if
             applicable)

          -  Willing to abstain from non-study related cannabis smoking throughout the study period
             (if applicable)

          -  No change in medication dosage or frequency of administration, with no exacerbations
             or hospitalizations in the preceding 4 weeks

        Exclusion Criteria:

          -  Presence of active and/or uncontrolled cardiopulmonary and/or musculoskeletal disease
             other than COPD that could contribute to breathlessness and exercise intolerance

          -  Hepatic or renal impairment

          -  Psychiatric history (other than depression and/or anxiety)

          -  History of epilepsy or convulsions;

          -  Lung cancer

          -  History of sensitivity to cannabis

          -  Use of levodopa, sildenafil and/or fentanyl

          -  Use of ketoconazole

          -  Use of regular high dose opioids (i.e., 30 mg of oral morphine equivalents/day)

          -  Known or suspected history of addiction/substance abuse based on CAGE-AID and SISAP
             scores (*note, patients may be recruited if they have a history of smoking cannabis)

          -  Positive urine toxicology for cannabinoids on screening

          -  Positive pregnancy urine test

          -  Subject cannot arrange to be accompanied home by a family member and/or friend during
             each treatment visit.
Clinical trial NCT03062462 (phase 2/phase 3, status: unknown status)
Conditions: coronary artery disease, clopidogrel, poor metabolism of
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: clopidogrel, ticagrelor
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with oral clopidogrel treatment admitted to hospital within 24 hours or
             long-term follow-up outpatients with oral clopidogrel treatment;

          2. The platelet aggregation rate (PAgR) measured with light transmission aggregometry
             (LTA) is decreased no more than 10% from baseline level, or PAgR is more than 46% and
             the percentage of inhibition of ADP-induced platelet aggregation measured by
             thrombelastogram is not more than 30%;

        Exclusion Criteria:

          1. Planned use of glycoprotein IIb/IIIa receptor inhibitors, adenosine diphosphate (ADP)
             receptor antagonists, or anticoagulant therapy during the study period;

          2. Platelet count <100g/L;

          3. Creatinine clearance rate < 30ml/min;

          4. Diagnosed as respiratory or circulatory instability (cardiac shock, severe congestive
             heart failure NYHA II-IV or left ventricular ejection fraction < 40%);

          5. A history of bleeding tendency;

          6. Aspirin, ticagrelor or clopidogrel allergies;

          7. Severe liver injury.
Clinical trial NCT03066193 (phase 2, status: completed)
Conditions: tourette syndrome
ICD codes: F95.2
Drugs: dronabinol and palmitoylethanolamide
SMILES: [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult between 18-60 years of age

          -  Meet DSM-5 criteria for the diagnosis of Tourette syndrome

          -  Significant current tic symptoms: YGTSS total tic score greater than or equal to 22 at
             baseline

          -  On stable psychiatric medication regimen for a minimum of 4 weeks prior to beginning
             the trial

          -  Accepted method of birth control

        Exclusion Criteria:

          -  Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental
             disorder or intellectual disability (IQ<70)

          -  Recent change (less than 4 weeks) in other medications that have potential effects on
             tic severity (such as alpha-2 agonists (guanfacine, clonidine or prazosin), SSRIs,
             clomipramine, naltrexone, lithium, anxiolytics, topiramate, baclofen etc.). Medication
             change is defined to include dose changes or medication discontinuation.

          -  Recent change in behavioral treatment for Tourette syndrome or comorbid conditions
             (i.e. OCD) within the last 4 weeks or initiation of behavioral therapy for tics within
             the last 12 weeks.

          -  Taking any co-medications (over the counter or prescription), food
             supplements/additives which can have a drug interaction with dronabinol or PEA.

          -  Positive pregnancy test or drug screening test

          -  History of cannabis dependence

          -  Significant Medical Comorbidity

          -  History of hypersensitivity to any cannabinoid or sesame oil
Clinical trial NCT03066219 (phase 2, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: brm421, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Provide written informed consent;

          -  Have a reported history of dry eye for at least 6 months prior to enrollment;

          -  Have a history of use of eye drops

        Exclusion Criteria:

          -  Have any clinically significant slit lamp findings at Visit 1 that may include active
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active
             ocular allergies that require therapeutic treatment, and/or in the opinion of the
             investigator may interfere with study parameters;

          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active
             ocular inflammation at Visit 1;

          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses
             during the study;

          -  Have used any eye drops within 2 hours of Visit 1;

          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the
             last 12 months;

          -  Be a woman of childbearing potential who is not using an acceptable means of birth
             control; acceptable methods of contraception
Clinical trial NCT03068754 (phase 2/phase 3, status: terminated)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: acthar, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    as recommended by the study's independent data and safety monitoring board (dsmb)
  
Eligibility criteria:

        Inclusion Criteria:

          1. Is 18-75 years of age at Screening

          2. Has ALS symptom onset within 2 years prior to Screening

          3. Has forced vital capacity (FVC) no higher than 60% at screening

          4. If taking riluzole, is on a stable dose for 4 weeks before Screening

        Exclusion Criteria:

          1. Has tracheostomy, diaphragm pacing, or an ongoing need for assisted ventilation of any
             type

          2. Has used any medication within a time period not allowed per protocol

          3. Has history of Type 1 or Type 2 diabetes mellitus, or any clinically significant
             infection

          4. Used edaravone less than 1 week before Screening

          5. Received any stem cell replacement therapy

          6. Used steroids within a time period not allowed per protocol
Clinical trial NCT03070782 (phase 2, status: completed)
Conditions: elevated lipoprotein(a), cardiovascular disease
ICD codes: E78.41, Z83.430, A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30
Drugs: isis 681257, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or
             peripheral artery disease

          -  Lp(a) plasma level ≥ 60 mg/dL

          -  Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD
             risk factors

        Key Exclusion Criteria:

          -  Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or
             stroke/TIA

          -  Within 3 months of Screening: coronary, carotid, or peripheral arterial
             revascularization, major non-cardiac surgery, or lipoprotein apheresis

          -  Heart failure New York Heart Association (NYHA) class IV
Clinical trial NCT03071263 (phase 2, status: completed)
Conditions: hyperkalemia, resistant hypertension
ICD codes: E87.5, P74.31, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: patiromer, placebo, spironolactone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Taking at least three medications for blood pressure (one a diuretic)

          -  Uncontrolled high blood pressure

          -  Abnormal kidney function (with-eGFR, a measure of kidney function, of 25 - ≤ 45
             mL/min/1.73m2

          -  Normal Blood serum Potassium in a specific range (4.3 - 5.1 mEq/L)

        Exclusion Criteria:

          -  History of untreated known causes of high blood pressure, excluding kidney disease
             (not CKD)

          -  Inability to measure BP

          -  Not taking high blood pressure medications as prescribed medications

          -  Recent change in renal function (in the past 3 months) which has required
             hospitalization or dialysis

          -  Renal transplant

          -  History of cancer within past 12 months

          -  Recent cardiovascular event with last 3 months

          -  Clinically significant abnormalities of heart rhythm (ventricular arrhythmia or atrial
             fibrillation with uncontrolled heart rate)

          -  Inability to take study medication

          -  Alcoholism
Clinical trial NCT03088605 (phase 2, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: top1630 ophthalmic solution, placebo to top1630 ophthalmic solution
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Provide written informed consent;

          -  Have a reported history of dry eye;

          -  Have a history of use of eye drops for dry eye symptoms;

        Additionally for Part 2

        Symptoms of dry eye syndrome including:

          -  Ocular discomfort

          -  Conjunctival redness

          -  Tear film break up time

          -  Schirmer test score

        Signs of dry eye syndrome including:

        Conjunctival staining score

        Exclusion Criteria:

          -  Have any clinically significant slit lamp findings at entry visit ;

          -  Be diagnosed with an ongoing ocular infection;

          -  Have any significant ocular lesion that could interfere with assessment of safety or
             efficacy or prevent study conduct in the opinion of the PI;

          -  Have any planned ocular and/or lid surgeries over the study period;

          -  Have an uncontrolled systemic disease;

          -  Be a woman who is pregnant, nursing or planning a pregnancy;

          -  Be a woman of childbearing potential who is not using an acceptable means of birth
             control;

          -  Have a known allergy and/or sensitivity to the test article or its components;

          -  Have a condition or be in a situation which the investigator feels may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with the subject's participation in the study;
Clinical trial NCT03091920 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2, hypertension
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: iw-1973, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is ambulatory male or female

          -  Patient's body mass index score is > 20 and < 40 kg/m^2 at the Screening Visit

          -  Women of childbearing potential must have a negative pregnancy test at the time of
             screening and check-in and must agree to use protocol-specified contraception
             throughout the duration of the study

          -  Patient's health is stable with no clinically significant findings on physical
             examination

          -  Patient has type 2 (ie, adult onset) diabetes mellitus diagnosed by a physician or
             nurse practitioner > 6 months before the Screening Visit, is on a stable glycemic
             control medication, and protocol specified hemoglobin (Hb)A1c values at the Screening
             Visit

          -  Patient has hypertension diagnosed by a physician or nurse practitioner > 6 months
             before the Screening Visit, and blood pressure (BP) within the protocol's acceptable
             range

          -  Patients must be on a stable regimen for hypertension control that includes an
             angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB),
             stable for 28 days

          -  Other inclusion criteria per protocol

        Exclusion Criteria:

          -  Patient has a clinically significant active or unstable medical condition that, in the
             opinion of the Investigator, would preclude trial participation

          -  Patient is on medication(s) that, when co-administered with a sGC stimulator, could
             increase the risk of hypotension

          -  Patient has evidence of severe or active end-organ damage

          -  Patient is an active smoker or has used any nicotine-containing products (cigarettes,
             e-cigarettes, vape pens, cigars, chewing tobacco, gum, patches) during the 6 months
             before Check-in. Use of nicotine is excluded during the study until after the End of
             Trial Visit.

          -  Other exclusion criteria per protocol
Clinical trial NCT03094195 (phase 2, status: terminated)
Conditions: post-herpetic neuralgia
ICD codes: G50.0, M54.81, B02.22, M79.2
Drugs: ema401, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was terminated early due to pre-clinical toxicity data that became available after
    start of trial
  
Eligibility criteria:

        Inclusion Criteria:

          -  At the time of Screening, must have had documented diagnosis of PHN (ICD-10 code
             B02.29), defined as pain in the region of the rash persisting for more than 6 months
             after onset of herpes zoster rash.

          -  Assessed as suffering from moderate to severe neuropathic pain across the Screening
             epoch (NRS ≥ 4).

          -  Patients must have had documented past and/or ongoing inadequate treatment response
             (having insufficient pain relief with treatment or inability to tolerate) to at least
             2 different prescribed therapies commonly used to treat and considered effective by
             the Investigator for the treatment of PHN.

          -  Patient must have been willing to complete daily eDiary

        Exclusion Criteria:

          -  History or had current diagnosis of electrocardiogram (ECG) abnormalities indicating
             significant risk of safety for patients participating in the study

          -  Had a major depressive episode within 6 months prior to Screening and/or a history of
             diagnosed recurrent major depressive disorder according to Diagnostic and Statistical
             Manual of Mental Disorders, 5th Edition (DSM-V) diagnostic criteria

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant.

          -  Had evidence of significant renal insufficiency or pre-existing liver condition

          -  Had platelets ≤ 100 x 10^9/L, or neutrophil count < 1.2 x 10^9/L (or equivalent),
             hemoglobin ≤ 100 g/L for women or hemoglobin ≤ 110 g/L for men.

          -  Patients who had a known diagnosis of diabetes and are stable on medication with a
             hemoglobin A1c > 8%. Those who did not have a known diagnosis of diabetes with a
             hemoglobin A1c > 7%.
Clinical trial NCT03098979 (phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: neladenoson bialanate (bay1067197), neladenoson bialanate (bay1067197), neladenoson bialanate (bay1067197), neladenoson bialanate (bay1067197), neladenoson bialanate (bay1067197), placebo
SMILES: C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women aged 45 years and older

          -  Diagnosis of chronic heart failure, NYHA (New York Heart Association) class II-IV,
             LVEF (left ventricular ejection fraction) ≥ 45% and elevated NT-proBNP

        Exclusion Criteria:

          -  Acute decompensated heart failure within the past 4 weeks

          -  Inability to exercise

          -  Previous diagnosis of HFrEF (heart failure with reduced ejection fraction) (LVEF <
             40%)
Clinical trial NCT03100058 (phase 2, status: completed)
Conditions: obesity, overweight
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211, E66.3
Drugs: lik066, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. informed consent

          2. (BMI>=30) or (BMI>=27 with history of CV disease, hypertension, dyslipidemia,
             pre-diabetes or type 2 diabetes mellitus, sleep-apnea syndrome)

          3. willing to comply with life-style intervention and treatment during the full duration
             of the study (approximately 54 weeks)

        Exclusion Criteria:

          -  Hypersensitivity to any of the study medications

          -  Pregnancy or lactating women

          -  History of malignancies

          -  Use of pharmacologically active weight loss products

          -  Bariatric surgery

          -  Ketoacidosis, lactic acidosis, hyperosmolar coma in the 6 months before the screening
             visit.

          -  HbA1c >10% at the screening visit.
Clinical trial NCT03100344 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: nemolizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects ≥ 18 years (or legal age when higher)

          -  Chronic AD, that has been present for at least 2 years before the visit

          -  Eczema Area and Severity Index (EASI) score ≥12

          -  Investigator Global Assessment (IGA) score ≥ 3

          -  AD involvement ≥ 10% of Body Surface Area (BSA)

          -  Severe pruritus on at least 3 of the last 7 days before the visit

          -  Documented recent history (within 6 months before the visit) of inadequate response to
             topical medications

          -  Female subjects must fulfill one of the criteria below:

               -  Female subjects of non-childbearing potential

               -  Female subjects of childbearing potential who agree to a true abstinence or to
                  use an effective or highly effective method of contraception throughout the
                  clinical trial and for 120 days after the last study drug administration

        Exclusion Criteria:

          -  Body weight < 45 kg

          -  subjects with a medical history of asthma requiring hospitalization in the last 12
             months before screening visit and/or whose asthma has not been well-controlled during
             the last 3 months before the screening visit and/or Peak Expiratory Flow (PEF) <80% of
             the predicted value

          -  Cutaneous bacterial or viral infection within 1 week before the screening visit or
             during the run-in period

          -  Infection requiring treatment with oral or parenteral antibiotics, antivirals,
             antiparasitics or antifungals within 1 week before the screening visit or during the
             run-in period

          -  History of intolerance to low or mid potency TCS or for whom TCS is not advisable